(via TheNewswire)
MultiXthick is a specially formulated, high density, pre-mixed barium suspension product. It will be sold in a 2-liter container and is for multiple testing applications. Barium sulfate suspension is for oral consumption to aid in radiographic x-ray procedures to view the upper gastrointestinal tract (esophagus, stomach, duodenum). MultiXthick is similar in composition to Voyageur's dry powdered HDX. However, the barite has been pre-mixed in solution with 58% barium and is designed to provide ultra-fine particle distribution for superior coating of the GI Tract.
Voyageur is continuing to develop multiple products and is currently developing its iopamidol-based Iodine contrast named IoX. The IoX product line is the focus in the near term for future submissions to
About Voyageur
Voyageur's goal is to generate positive cash flow from operations through its signed joint venture with Chief Medical Supply Ltd. -
About
Voyageur formed ImagingX, a gross revenue-sharing joint venture company with Chief Medical Supply Ltd (CMS). CMS provides high quality, competitively priced pharmaceuticals and hemodialysis products to pharmacies and hospitals in
ImagingX is employing a strategy of selling competitively priced radiopharmaceuticals for MRI, X-ray and CT scan applications. The main focus to date has been on barium, with the inclusion of iodine in 2020. The joint venture obligates Voyageur to provide the Active Pharmaceutical Ingredient minerals for the products and CMS to manufacture the products. The partners each split gross revenue 50/50. This joint venture relationship is designed for ImagingX to be highly competitive by controlling all input costs under the motto of:
"From the Earth to the Bottle"
For further information, please contact:
Mobile + (403) 471-1659
Office: + (587)-779-6166 Dial #1
steve@voyageurminerals.ca
www.voyageurpharmaceuticals.ca
Reader Advisory
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Statements:
This news release contains certain statements or disclosures relating to the Company that are based on the expectations of its management as well as assumptions made by and information currently available to the Company which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results or developments that the Company anticipates may or will occur in the future (in whole or in part) should be considered forward-looking statement and undue reliance should not be placed on any such statements. In some cases, forward-looking statements can be identified by the use of the words "will", "intends", "believes", "expects", forecasts", "anticipates", "plans" and similar expressions.
In particular, but without limiting the foregoing, this news release contains forward-looking statements pertaining toanticipated product registrations with
The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in
Copyright (c) 2020 TheNewswire - All rights reserved.
Copyright (c) 2020 TheNewswire - All rights reserved., source